ICP
CRSP icon

Interchange Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Interchange Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-600
Closed -$23.6K – 303
2024
Q4 		$23.6K Hold
600
– – 0.01% 259
2024
Q3 		$28.2K Hold
600
– – 0.01% 274
2024
Q2 		$32.4K Buy
+600
New +$34.7K 0.01% 273

Other funds holding CRSP

EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Interchange Capital Partners's CRSP Position: Q2 2026 in Review

Interchange Capital Partners reduced its CRISPR Therapeutics (CRSP) stake by 34% in Q2 2026, selling an estimated $120K and leaving 4,498 shares worth $245K. The position accounts for 0.05% of the portfolio, ranked #354.

Interchange Capital Partners first reported a position in CRSP in Q4 2020 and has held it in 20 quarters since. The position peaked at $1.49M in Q4 2020. 109 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Interchange Capital Partners held 4,498 shares of CRISPR Therapeutics worth $245K as of Q2 2026.
  • Interchange Capital Partners sold 2,269 CRISPR Therapeutics shares in Q2 2026, an estimated $120K.
  • CRISPR Therapeutics made up 0.05% of Interchange Capital Partners's portfolio in Q2 2026, its #354 holding.
  • Interchange Capital Partners first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Interchange Capital Partners's CRISPR Therapeutics position peaked at $1.49M in Q4 2020.
  • 109 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.